Back to results

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Primary Purpose

Pancreatectomy for Chronic Pancreatitis

Status

Completed

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

Reparixin

Placebo

About this trial

This is an interventional treatment trial for Pancreatectomy for Chronic Pancreatitis focused on measuring Pancreatic islet auto-transplantation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients eligible for an IAT following total (or completion) pancreatectomy.
Ages > 18 years.
Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations.
Patients who have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.

Exclusion Criteria:

Recipients of a previous IAT (if completion pancreatectomy).
Patients undergoing total pancreatectomy due to either pancreatic cancer or pancreatic benign diseases other than chronic pancreatitis, including insulinomas, etc.
Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr) < 60 mL/min according to the Cockcroft-Gault formula (1976).
Patients with hepatic dysfunction as defined by increased ALT/AST > 3 x upper limit of normal (ULN) or increased total bilirubin above the upper limit at local laboratory). Patients with Gilbert's syndrome (elevated unconjugated bilirubin levels in the absence of any evidence of hepatic or biliary tract disease) are not excluded.
Patients with a preoperative International Normalized Ratio (INR) > 1.5 or any known coagulopathy.
Hypersensitivity to:
1. ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID).
2. medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.
Concurrent sepsis (as per positive blood culture(s) and/or fever associated with other signs of systemic sepsis syndrome).
Treatment with systemic steroids in the 2 weeks prior to enrolment (except for the use of <5mg prednisone daily or equivalent dose of hydrocortisone, for physiological replacement only) or with any immune modulators in the 4 weeks prior to enrolment.
Patients with pre-existing diabetes or evidence of impaired β-cells function, based on pre-operative fasting blood glucose >115 mg/dL and/or a HbA1c > 6.5%, or requiring treatment with any anti-diabetic medication (e.g. insulin, metformin, etc) within the 2 weeks prior to enrolment.
Use of any investigational agent in the 4 weeks prior to enrolment, including any anti-cytokine/chemokine agents.
Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males). (NB: pregnancy should be avoided in patients or partners during the first month after completing the treatment with the Investigational Product; no other specific warnings are described, considering the treatment course of the Investigational Product, its PK profile, and the lack of significant adverse effects on mating performance and fertility in animal studies).
Patients with past or current history of alcohol abuse based on clinical history and/or past treatment for alcohol addiction.
Patients with evidence of pre-operative portal hypertension as per clinical history and abdominal/liver imaging by ultrasound techniques.

Sites will comply with any additional or more restrictive exclusion criteria locally accepted, as per centre practice.

Sites / Locations

University of California. Department of Surgery, Division of Transplantation
The University of Chicago Medical Center
Schulze Diabetes Institute University of Minnesota Medical School
Dartmouth-Hitchcock Medical Center
The University of Cincinnati Medical Center
Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center
Medical University of South Carolina
Baylor University Medical Center
University of Alberta, Clinical Islet Transplant Program

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Reparixin

Placebo

Arm Description

Solution for intravenous (IV) infusion with active compound

Physiologic solution

Outcomes

Primary Outcome Measures

Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant.

Insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycemic control, as defined by: a glycated hemoglobin (HbA1c) level <6.5%; fingerstick fasting blood glucose not exceeding 126 mg/dL more than three times in the past week (based on a minimum of one daily measurement; a 2 hour post-prandial blood glucose not exceeding 180 mg/dL more than four times in the past week (based on a minimum of one daily measurement); a laboratory fasting glucose in the non-diabetic range (<126 mg/dL).

Secondary Outcome Measures

Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant

AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg

Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant

AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg

Average Daily Insulin Requirements at Day 75±14 After the Transplant

Daily insulin is reported as IU/kg and intake averaged over the previous week.

Average Daily Insulin Requirements at Day 365±14 After the Transplant

Daily insulin is reported as IU/kg and intake averaged over the previous week.

Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Data of this outcome are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=42; 46 30 min; N=40; 46 60 min; N=40; 46 90 min; N=40; 46 120 min; N=41; 46 180 min; N=40; 46 240 min; N=39; 44

Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Data are reported as "model estimates over all timepoints" This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 42 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 41

Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=44; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=42; 47 90 min; N=42; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44

Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=33; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 40 240 min; N=33; 41

Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=43; 48 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=43; 47 30 min; N=41; 47 60 min; N=41; 47 90 min; N=41; 47 120 min; N=42; 47 180 min; N=41; 47 240 min; N=40; 44

Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal) 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 40

β-cell Function at Day 75±14 After the Transplant

This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for: fasting plasma glucose, HbA1c, stimulated C-peptide insulin requirement subscales. The higher the total score, the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)

β-cell Function at Day 365±14 After the Transplant

This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales. The higher the total score the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)

Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant

Percentage of patients with a glycated haemoglobin (HbA1c) <6.5% at day 365±14 after the transplant.

Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant

A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.

Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive

Percentage of patients with an HbA1c <6.5% at day 365±14 after the transplant AND free of severe hypoglycemic events from day 75±14 to day 365±14 after the transplant inclusive.A severe hypoglycemic event is defined as an event with one of the following symptoms: "memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms", in which the subject was unable to treat him/herself and which was associated with either a blood glucose level <54mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.

Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study

The percentages of patients with any treatment emergent adverse events (TEAE, serious and non serious) and with serious TEAE by severity are presented. Patients with multiple events within a particular system organ class or preferred term were counted only under the category of their most severe event within that system organ class or preferred term. A serious AE was defined as any untoward medical occurrence that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event) Required inpatient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was a congenital anomaly/birth defect Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above

Proportion of Patients Falling Into One of the Following Malnutrition Risk Levels (Poor Prognosis, Significant Risk, Increased Risk, Normal) According to Pre-albumin Level at Day 75±14 After the Transplant

Malnutrition risk levels are defined as: Poor prognosis = pre-albumin level <5.0 mg/dL Significant risk = pre-albumin level 5.0 to 10.9 mg/dL Increased risk = pre-albumin level 11.0 to 15.0 mg/dL Normal = pre-albumin level > 15.0 (up to 35.0) mg/dL

Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant

Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.

Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant

Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.

Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant

The following definition applies: - Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration <70mg/dL.

Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant

The following definition applies: - Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration <70mg/dL.

Cumulative Number of Diabetic Ketoacidosis-related Events

A diabetic ketoacidosis event is defined as the presence of: hyperglycemia (blood glucose >200 mg/dL); pH <7.3 or HCO3 <15; ketones positive in the serum or urine.

Peak C-peptide at Day 75 After the Transplant

Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.

Peak C-peptide at Day 365 After the Transplant

Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.

Time-to-peak C-peptide at Day 75 After the Transplant

The time-to-peak value in minutes was computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test Case Report Form.

Time-to-peak C-peptide at Day 365 After the Transplant

The time to peak value in minutes will be computed as the time of the peak value (HH:MM on a 24-hour clock) minus the end time of the mixed meal (HH:MM on a 24-hour clock) as recorded on the mixed meal tolerance test CRF.

Change From Baseline in Post-transplant Alanine Aminotransferase (ALT)

Data are reported as "model estimates over all timepoints". This safety parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: baseline; N=50; 52 Day 2 post-transplant; N=49; 51 Day 3 post-transplant; N=47; 50 Day 7 post-transplant; N=47; 50 Day 75 post-transplant; N=44; 47

Change From Baseline in Post-transplant Aspartate Aminotransferase (AST)

Number of Treatment Emergent Adverse Events Related to Investigational Product

Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called "Adverse reactions" (ADR). An adverse reaction is defined as any untoward medical occurrence in a patient or clinical investigation patient, which has a causal relationship with the administered medicinal product.

Number of Serious Treatment Emergent Adverse Events Related to Investigational Product

Serious Treatment emergent adverse events - possibly, probably and highly probably - related to investigational product are called serious "Adverse reactions". A serious adverse reaction is defined as any untoward medical occurrence with a causal relationship with the administered medicinal product, that at any dose: Resulted in death Was life-threatening (ie, the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.) Required patient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was an important medical event that, based upon appropriate medical judgment, may have jeopardized the patient and may have required medical or surgical intervention to prevent one of the outcomes listed above

Full Information

NCT ID

NCT01967888

First Posted

October 18, 2013

Last Updated

July 17, 2023

Sponsor

Dompé Farmaceutici S.p.A

1. Study Identification

Unique Protocol Identification Number

NCT01967888

Brief Title

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Official Title

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Study Type

Interventional

2. Study Status

Record Verification Date

July 2023

Overall Recruitment Status

Completed

Study Start Date

February 2014 (Actual)

Primary Completion Date

January 2018 (Actual)

Study Completion Date

January 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Dompé Farmaceutici S.p.A

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The study is a phase 2/3, multicenter, double-blind, parallel assignment study. It involves 100 adult recipients of an intra-hepatic pancreatic Islet Auto-Transplantation (IAT). The objective of this clinical trial is to assess whether reparixin leads to improved transplant outcome as measured by the proportion of insulin-independent patients following IAT. The safety of reparixin in the specific clinical setting will be also evaluated.

Detailed Description

In contrast to allo-transplantation in type 1 diabetes patients, where immunological mechanisms involving allo- and auto-antibodies affect long-term graft function, outcome in IAT (Islet Auto-Transplantation) is independent from immunological processes and does not require immunosuppression management. On the other hand, early inflammatory events intrinsic to the intra-portal islet infusion have been demonstrated to impact islet engraftment. Among possible mechanisms, PMNs have been found to be the predominant cell types infiltrating the liver in a syngeneic model of islet transplantation in mice. Data obtained in experimental models of islet transplantation in mice demonstrate a clear effect of reparixin in improving graft survival and function. Protection from the loss and/or deterioration of transplanted islets was evident regardless of the immunological mechanisms involved in islet damage, suggesting that the ability of reparixin to modulate early inflammatory responses readily impact graft outcome. Thus, the use of reparixin may emerge as a potential useful medication in the control of non specific inflammatory events surrounding the early phases of IAT. The goal of this study is to reach a total of 100 adult patients who are randomized and receive IAT after total or completion pancreatectomy. Patients will be randomly (1:1) assigned to receive either reparixin [continuous i.v. infusion for 7 days (168hrs)], or matched placebo (control group),starting approximately 12hrs before islet infusion. The two groups will be balanced within each centre. All patients who are randomized and receive the Investigational Product (either reparixin or placebo) will be included in the ITT analysis. Patients will be in the ITT analysis whether or not they receive IAT, because exclusions cannot be made for events occurring after randomization that could be influenced by the randomized assignment. Recruitment will be competitive among the study sites, until the planned number of patients is enrolled. Competitive recruitment has been chosen to increase the speed of recruitment and to account for any difference in transplant rate among study sites. Each centre will enroll patients as rapidly as possible, up to a maximum of 40 patients (as per the randomization list). A maximum of 48 patients is allowed for the site of the Primary Investigator. Each patient will be involved in the study for 7 day hospital stay during pancreatectomy followed by islet transplantation, for all required measurements up to hospital discharge and for 2 post-transplant visits scheduled @ day 75+14 and 365+14 after the transplant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pancreatectomy for Chronic Pancreatitis

Keywords

Pancreatic islet auto-transplantation

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2, Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

104 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Reparixin

Arm Type

Experimental

Arm Description

Solution for intravenous (IV) infusion with active compound

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Physiologic solution

Intervention Type

Drug

Intervention Name(s)

Reparixin

Other Intervention Name(s)

DF1681Y

Intervention Description

Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Physiologic solution administered at 0.25 mL/kg/hour

Primary Outcome Measure Information:

Title

Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant.

Description

Time Frame

day 365±14 after the transplant

Secondary Outcome Measure Information:

Title

Area Under the Curve (AUC) for the Serum C-peptide Level at Day 75±14 After the Transplant

Description

AUC for the serum C-peptide level is calculated during the first 4 hours of an MMTT, normalized by the number of Islet Equivalent (IEQ)/kg

Time Frame

day 75±14 after the transplant

Title

Area Under the Curve (AUC) for the Serum C-peptide Level at Day 365±14 After the Transplant

Description

AUC for the serum C-peptide level is calculated during the first 4 hours of a mixed meal tolerance test (MMTT), normalized by the number of Islet Equivalent (IEQ)/kg

Time Frame

day 365±14 after the transplant

Title

Average Daily Insulin Requirements at Day 75±14 After the Transplant

Description

Daily insulin is reported as IU/kg and intake averaged over the previous week.

Time Frame

day 75±14 after the transplant

Title

Average Daily Insulin Requirements at Day 365±14 After the Transplant

Description

Daily insulin is reported as IU/kg and intake averaged over the previous week.

Time Frame

day 365±14 after the transplant

Title

Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Description

Time Frame

day 75±14 after the transplant

Title

Time Course From Basal to 240 Min of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Description

Time Frame

day 365±14 after the transplant

Title

Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Description

Time Frame

day 75±14 after the transplant

Title

Time Course From Basal to 240 Min of C-peptide Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Description

Data are reported as "model estimates over all timepoints". This parameters was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=33; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal). 15 min; N=34; 41 30 min; N=34; 41 60 min; N=33; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 40 240 min; N=33; 41

Time Frame

day 365±14 after the transplant

Title

Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 75±14 After the Transplant

Description

Time Frame

day 75±14 after the transplant

Title

Time Course From Basal to 240 Min of Insulin Derived From the Mixed Meal Tolerance Test (MMTT) at Day 365±14 After the Transplant

Description

Data are reported as "model estimates over all timepoints". This parameter was assessed at the following timepoints on the following numbers of patients for Reparixin and placebo, respectively: basal; N=34; 41 (Basal is: 2 basal samples taken separately between -20 to 0 minutes before the meal followed by samples through 240 minutes after the meal) 15 min; N=34; 41 30 min; N=34; 41 60 min; N=34; 41 90 min; N=34; 41 120 min; N=34; 41 180 min; N=33; 41 240 min; N=33; 40

Time Frame

day 365±14 after the transplant

Title

β-cell Function at Day 75±14 After the Transplant

Description

Time Frame

day 75±14 after the transplant

Title

β-cell Function at Day 365±14 After the Transplant

Description

This variable is assessed by β-score (assessment of β-cell function after islet transplantation). The total score is calculated on a 0-8 scoring system (higher is a better outcome) that gives 0-2 points each for glucose, HbA1c, stimulated C-peptide and insulin requirement subscales. The higher the total score the better the outcome. Fasting (or before breakfast) plasma glucose (mg/dL) : ≤99, Score 2; 100-124, Score 1; ≥ 125, Score 0 (the higher the subscore the better the outcome) HbA1c (%): ≤6.1, Score 2; 6.2-6.9, Score 1; ≥ 7.0, Score 0 (the higher the subscore the better the outcome) Daily average (previous week) insulin (IU/kg/day): ---, Score 2; 0.01-0.24, Score 1; ≥ 0.25, Score 0 (the higher the subscore the better the outcome) Stimulated C-peptide (ng/mL): ≥ 0.9, Score 2; 0.3-0.89, Score 1; ≤0.3, Score 0 (the higher the subscore the better the outcome)

Time Frame

day 365±14 after the transplant

Title

Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant

Description

Percentage of patients with a glycated haemoglobin (HbA1c) <6.5% at day 365±14 after the transplant.

Time Frame

day 365±14 after the transplant

Title

Cumulative Number of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant

Description

Time Frame

from day 75±14 to day 365±14 after the transplant

Title

Proportion of Patients With an HbA1c <6.5% at Day 365±14 After the Transplant AND Free of Severe Hypoglycemic Events From Day 75±14 to Day 365±14 After the Transplant Inclusive

Description

Time Frame

from day 75±14 to day 365±14 after the transplant

Title

Incidence and Severity of Adverse Events and Serious Adverse Events Throughout the Study

Description

Time Frame

up to day 365±14 after the transplant

Title

Description

Time Frame

day 75±14 after the transplant

Title

Description

Time Frame

day 365±14 after the transplant

Title

Proportion of Patients by Steatorrhea Severity at Day 75±14 After the Transplant

Description

Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.

Time Frame

day 75±14 after the transplant

Title

Proportion of Patients by Steatorrhea Severity at Day 365±14 After the Transplant

Description

Levels of steatorrhea severity (evaluated in the 4 weeks prior to day 75±14 and 365±14), are defined as: No steatorrhea; Steatorrhea few times per week; Steatorrhea daily; Stool incontinence.

Time Frame

day 365±14 after the transplant

Title

Cumulative Number of Episodes of Documented Asymptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant

Description

The following definition applies: - Asymptomatic hypoglycemia = An event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration <70mg/dL.

Time Frame

from day 75±14 to day 365±14 after the transplant

Title

Cumulative Number of Episodes of Documented Symptomatic Hypoglycemia From Day 75±14 to Day 365±14 After the Transplant

Description

The following definition applies: - Documented symptomatic hypoglycemia = An event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration <70mg/dL.

Time Frame

from day 75±14 to day 365±14 after the transplant

Title

Cumulative Number of Diabetic Ketoacidosis-related Events

Description

A diabetic ketoacidosis event is defined as the presence of: hyperglycemia (blood glucose >200 mg/dL); pH <7.3 or HCO3 <15; ketones positive in the serum or urine.

Time Frame

from day 75±14 to day 365±14 after the transplant

Title

Peak C-peptide at Day 75 After the Transplant

Description

Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.

Time Frame

Day 75±14 after the transplant

Title

Peak C-peptide at Day 365 After the Transplant

Description

Peak C-peptide (C-P) is a known predictor of Type 1 Diabetes.

Time Frame

Day 365±14 after the transplant

Title

Time-to-peak C-peptide at Day 75 After the Transplant

Description

Time Frame

day 75±14 and day 365±14 after the transplant

Title

Time-to-peak C-peptide at Day 365 After the Transplant

Description

Time Frame

Day 365±14 after the transplant

Title

Change From Baseline in Post-transplant Alanine Aminotransferase (ALT)

Description

Time Frame

Baseline, Days 2, 3, 7, 75 ±14 after the transplant

Title

Change From Baseline in Post-transplant Aspartate Aminotransferase (AST)

Description

Time Frame

Baseline, Days 2, 3, 7, 75±14 after the transplant

Title

Number of Treatment Emergent Adverse Events Related to Investigational Product

Description

Time Frame

Throughout the study From Day -1 to hospital discharge

Title

Number of Serious Treatment Emergent Adverse Events Related to Investigational Product

Description

Time Frame

Throughout the study From Day -1 to hospital discharge for all adverse events, and from then to day 365 post-transplantation only for serious adverse events

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Patients eligible for an IAT following total (or completion) pancreatectomy. Ages > 18 years. Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations. Patients who have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. Exclusion Criteria: Recipients of a previous IAT (if completion pancreatectomy). Patients undergoing total pancreatectomy due to either pancreatic cancer or pancreatic benign diseases other than chronic pancreatitis, including insulinomas, etc. Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr) < 60 mL/min according to the Cockcroft-Gault formula (1976). Patients with hepatic dysfunction as defined by increased ALT/AST > 3 x upper limit of normal (ULN) or increased total bilirubin above the upper limit at local laboratory). Patients with Gilbert's syndrome (elevated unconjugated bilirubin levels in the absence of any evidence of hepatic or biliary tract disease) are not excluded. Patients with a preoperative International Normalized Ratio (INR) > 1.5 or any known coagulopathy. Hypersensitivity to: ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID). medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib. Concurrent sepsis (as per positive blood culture(s) and/or fever associated with other signs of systemic sepsis syndrome). Treatment with systemic steroids in the 2 weeks prior to enrolment (except for the use of <5mg prednisone daily or equivalent dose of hydrocortisone, for physiological replacement only) or with any immune modulators in the 4 weeks prior to enrolment. Patients with pre-existing diabetes or evidence of impaired β-cells function, based on pre-operative fasting blood glucose >115 mg/dL and/or a HbA1c > 6.5%, or requiring treatment with any anti-diabetic medication (e.g. insulin, metformin, etc) within the 2 weeks prior to enrolment. Use of any investigational agent in the 4 weeks prior to enrolment, including any anti-cytokine/chemokine agents. Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males). (NB: pregnancy should be avoided in patients or partners during the first month after completing the treatment with the Investigational Product; no other specific warnings are described, considering the treatment course of the Investigational Product, its PK profile, and the lack of significant adverse effects on mating performance and fertility in animal studies). Patients with past or current history of alcohol abuse based on clinical history and/or past treatment for alcohol addiction. Patients with evidence of pre-operative portal hypertension as per clinical history and abdominal/liver imaging by ultrasound techniques. Sites will comply with any additional or more restrictive exclusion criteria locally accepted, as per centre practice.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Melena Bellin, MD

Organizational Affiliation

Schulze Diabetes Institute; University of Minnesota Amplatz Children's Hospital

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of California. Department of Surgery, Division of Transplantation

City

San Francisco

State/Province

California

ZIP/Postal Code

94143

Country

United States

Facility Name

The University of Chicago Medical Center

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60637

Country

United States

Facility Name

Schulze Diabetes Institute University of Minnesota Medical School

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55455

Country

United States

Facility Name

Dartmouth-Hitchcock Medical Center

City

Lebanon

State/Province

New Hampshire

ZIP/Postal Code

03756

Country

United States

Facility Name

The University of Cincinnati Medical Center

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45219

Country

United States

Facility Name

Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15213

Country

United States

Facility Name

Medical University of South Carolina

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29425

Country

United States

Facility Name

Baylor University Medical Center

City

Dallas

State/Province

Texas

ZIP/Postal Code

75246

Country

United States

Facility Name

University of Alberta, Clinical Islet Transplant Program

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 2C8

Country

Canada

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

We'll reach out to this number within 24 hrs